Pfizer turns to app to overcome rare disease enrollment bottleneck

Pfizer ($PFE) is experimenting with a mobile app to enroll rare disease patients in a study. The trial is comparing the DNA of people with congenital analgesia to unaffected family members, but with just 40 new cases diagnosed each year, enrollment is a challenge. Pfizer hopes Sanguine Biosciences' mobile app can help by enabling remote data collection. Article